AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
AbbVie(ABBV) stock is priced at $289.92, giving the company a market capitalization of 512.47B. It carries a P/E multiple of 49.61 and pays a dividend yield of 2.40%.
As of 2026-11-06, AbbVie(ABBV) stock has fluctuated between $281.07 and $291.71. The current price stands at $289.92, placing the stock +3.1% above today's low and -0.6% off the high.
The AbbVie(ABBV)'s current trading volume is 2.36M, compared to an average daily volume of 5.74M.
In the last year, AbbVie(ABBV) shares hit a 52-week high of $302.93 and a 52-week low of $190.75.
In the last year, AbbVie(ABBV) shares hit a 52-week high of $302.93 and a 52-week low of $190.75.
ABBV News
Six household-name dividend payers hand you a steady paycheck, but one of them gets taxed far harder than the other five. Find out which holding belongs in a Ro...
AbbVie guidance boost and dividend move draw fresh investor focus AbbVie (ABBV) has just paired a higher full year outlook with a dividend increase and a run o...
Abbvie (ABBV) announced an update on their ongoing clinical study. Study Overview: AbbVie is studying a new injectable combination for moderate to severe upper...
Analyst ratings
75%
of 32 ratingsMore ABBV News
Abbvie (ABBV) announced an update on their ongoing clinical study. Study Overview: AbbVie’s NCT07649954 trial, titled “A Phase 1 Open-Label, Two-Period Study t...
AbbVie (NYSE: ABBV) and Brise Pharmaceuticals signed an exclusive global license to co develop next generation migraine therapies. Brise will advance preclinic...
Shares of AbbVie (NYSE:ABBV) tanked in early trading on Monday after the company reported its third-quarter results on Friday. Here are some key analyst takeaw...
Is your portfolio ready for the shifting landscape of modern medicine? Choosing between AbbVie Inc. (ABBV -1.91%) and Bristol Myers Squibb Co. (BMY +0.18%) depe...
AbbVie Inc. (NYSE:ABBV) on Friday reported better-than-expected third-quarter 2026 results and raised its full-year outlook. AbbVie reported third-quarter sale...
On CNBC’s “Halftime Report Final Trades,” Jason Snipe, founder and chief investment officer of Odyssey Capital Advisors, recommended AbbVie Inc. (NYSE:ABBV). O...
AbbVie (ABBV +1.41%) has already pulled off one of the great commercial pivot stories in pharmaceutical history. When Humira -- once pharma's top-selling drug -...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.